


PROGRAM



# Bio-Neuroscience

Amsterdam, 24th-26th February, 2026

THE GLOBAL SUMMIT FOR LEADERS  
AND DECISION-MAKERS IN  
NEUROSCIENCES DRUG  
DEVELOPMENT

Key Opinion Leaders  
Industry Executives  
Startups Founders  
C-level Executives  
Investors



INSIGHT - ACCESS - ENGAGEMENT - IMPACT

AN INITIATIVE OF



CO-ORGANIZED WITH





14:00

## COFFEE & REGISTRATION

14:30

## Roundtable Networking - Coffee and a Series of Networking Tables

Participant networking at a series of pre-scheduled roundtables for accelerated introductory networking.

15:00

## Pre-Summit Roundtable Discussion - Innovation in BoNT Based Therapies for Neurological and Psychiatric Disorders

**Moderator:** Christian J Suojanen, CEO - Broadreach Global

Stefan König	CEO - Merz Therapeutics
Eric Finzi	Co-Founder - Healis Therapeutics
Marc Axel Wollmer	Head of department, Department of Old Age Psychiatry - Asklepios Clinic North - Ochsenzoll
Tillmann Krüger	Associate Professor, Deputy Head of Department - Psychiatry, Social Psychiatry and Psychotherapy, Head of Section of Clinical Psychology & Sexual Medicine - Hannover Medical School

15:45

## COFFEE BREAK

16:00

## Welcome to Bio-Neuroscience: Official Inauguration

Christian J Suojanen	CEO - Broadreach Global
Andrea Soto Padilla	Business Development - Amsterdam Neuroscience, Amsterdam UMC

16:30

## The need for Innovation in Pre-Clinical and Para-Clinical Models

**Moderator:** Christian J Suojanen, CEO - Broadreach Global

José Luís Lanciego	Laboratory of Gene Therapy for Parkinson's Disease - CIMA, University of Navarra, & President - European Brain Foundation
Claudia Persoon	Head - Neurospecter
Joshua Bagely	Chief Scientific Officer - ahead bio AG



# DAY I

TUESDAY 24 FEB. 2026



## Bio-Neuroscience

17:15

### **Innovation in Biomarkers to accelerate clinical research and improve clinical care**

Joachim Reischl

VP & Franchise Head, Neurodegenerative Disease, Center of Innovation - Danaher Diagnostics

Charlotte Teunissen

Professor in Neurochemistry - Amsterdam UMC

18:00

### **Welcome Reception Remarks**

18:05

### **WELCOME RECEPTION & NETWORKING**



## Bio-Neuroscience



Bio-Neuroscience



08:15

## REGISTRATION OPENS, COFFEE & NETWORKING

09:00

### Opening Remarks

Christian J Suojanen

CEO – Broadreach Global

Pieter van Bokhoven

Chief Scientific Officer - IXA Amsterdam  
Neuroscience UMC

09:15

### The Regulatory Perspective in Neuroscience Drug Development

**Moderator:** Philip Scheltens, Managing Partner – EQT Dementia Fund, Partner EQT Life Sciences

Violeta Stoyanova-Beninska

Senior Scientific Specialist, Office of Therapies for neurological and psychiatric disorders  
Former Chair of Committee for Orphan Medicinal Products - European Medicines Agency  
Chair of Regulatory Science Committee - International Rare Disease Research Consortium

10:00

### Therapeutics Development for Rare Neurological Diseases; Financing, Clinical and Regulatory Challenges and the Patient and Startup Perspective

#### Discussion Panel

**Moderator:** Yael Weiss, CEO - Mahzi Therapeutics

A discussion with stakeholders in rare pediatric neurological disease innovation; from rare families developing therapies, to KOL collaborators and specialized industry partners.

Stuart Cobb

Chief Scientific Officer- Neurogene Inc,  
Professor of Translational Neuroscience - The University of Edinburgh

Andy Stevenson

Head of Fundraising - Reverse Rett

10:45

## NETWORKING COFFEE BREAK



11:15

**The Investment Bank Perspective: Navigating the State of Capital Markets and M&A as it impacts Neuroscience Drug Development**

**Moderator:** Bruce Leuchter, President & CEO - Neurvati Neurosciences

Kevin Sheridan	Joint Global Head of Healthcare Investment Banking - Jefferies LLC
Eric Stewart	Senior Managing Director, Healthcare Mergers & Acquisitions - Leerink Partners
Sven Pfeiffer	Partner, Strategic Advisory Group - PJT Partners

12:00

**Investor Session – The current Investment Landscape for CNS Neuroscience Drug Development**

In light of evolving geopolitical, market, and regulatory conditions - what does it mean for private biotech?

**Moderator:** Hakan Goker, Managing Director & Head of Life Sciences – M Ventures

Thomas Michael Thestrup	Senior Principal - Angelini Ventures
Henrijette Richter	Managing Partner - Sofinnova Partners
Joao Barbosa da Silva	Investor - re.Mind Capital
Keno Gutierrez	General Partner - BioGeneration Ventures (BGV)

12:45

**LUNCH & NETWORKING BREAK - HOSTED BY MERZ THERAPEUTICS**



**THERAPEUTICS**

Better outcomes for more patients.

14:00

**Fireside Chat – A Strategic Venture to develop a Disease Modifying Therapy for GBA Parkinson’s Disease**

**Moderator:** Kees Been, CEO, Kynexis Therapeutics

António Portela	CEO - BIAL
-----------------	------------



14:45

**Neuroinflammation; tackling indications from MS to PD and AD**  
Key advances, core challenges, and strategies going forward in current market conditions.

**Moderator:** Marco Giorgetti, Global Head Alliance Management, Danaher

Jing Wang	Co-Founder & Chief Executive Officer - Myrobalan Therapeutics
Marcelo Bigal	President & Chief Executive Officer - Ventus Therapeutics
Niels Plath	Chief Scientific Officer - Muna Therapeutics

15:30

**NETWORKING COFFEE BREAK**

16:00

**Venture Philanthropy, Charity and Foundation Financed Neuroscience Drug Development**

**Moderator:** Andrea Soto Padilla, Business Development - Amsterdam Neuroscience, Amsterdam UMC

Giovanna Lalli	Director of Strategy & Operations - LifeArc
Opher Kornfeld	Director, Translational Research and Development - SPARK NS
Lynsey Bilisland	Managing Director of Parkinson's Virtual Biotech - Parkinson's UK

16:45

**COMPANY PRESENTATION SESSION**

Selected companies present to an industry & investor panel

AlzeCure Pharma - Martin Jönsson - CEO
London Research & Pharmaceuticals Corporation - Abdelrahman Lawendy - CEO
discoveric bio alpha - Oliver Eckelmann - CEO
FundaMental Pharma GmbH - Dirk Beher - CEO
Mair Therapeutics - Vasily Kazey - CEO
TRIMTECH Therapeutics - Nicki Thompson - CEO

17:45

**END OF DAY II & NETWORKING RECEPTION - HOSTED BY DANAHER**





08:15

## REGISTRATION OPENS, COFFEE & NETWORKING

09:00

## Keynote - Engineering AAVs for human CNS Gene Therapy

Ben Deverman

Director, Vector Engineering at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard

10:00

## Gene therapy 2.0 in Neuroscience

The evolution of gene therapies, current approaches, opportunities and challenges from the scientific, clinical, regulatory and market perspectives.

**Moderator:** Robert Thorne, Denali Fellow – Denali Therapeutics, President - International Brain Barriers Society (IBBS)

Alex Bloom

CTO - AviadoBio

Andrew Steinsapir

Acting CTO - Apertura Gene Therapy, & Director, Gene Therapy Program Lead - Deerfield Management

Marco Weinberg

Senior Vice President, Head of Research, uniQure

Sander van Deventer

President R&D, VectorY Therapeutics

10:45

## NETWORKING COFFEE BREAK

11:15

## Fireside Chat - Anatomy of a deal; Discussing the Angelini Pharma and GRIN Therapeutics deal, one year in

**Moderator:** Christian J. Suojanen, CEO – Broadreach Global

Jacopo Andreose

Board Member - Angelini Industries and and Grin Therapeutics

Bruce Leuchter

President & CEO - Nervati Neurosciences

12:00

## Novel modalities, from Oligonucleotides to RNA Therapeutics in CNS Rare Diseases: Science, Approvals, Approaches and Deals.

**Moderator:** Pieter van Bokhoven, Chief Scientific Officer - IXA Amsterdam Neuroscience UMC

Maria Luisa Pineda

CEO & Co-Founder - Envisagenics

Tarek Samad

Senior Vice President & Global Head of Research - Lundbeck

Vikas Sharma

Chief Business Officer - QurAlis





12:45

**LUNCH & NETWORKING BREAK**

14:00

**COMPANY COMPANY SESSION**

Selected companies present to an industry & investor panel

Contineum Therapeutics - Daniel S. Lorrain - CSO
Priavoid GmbH - Antje Willuweit - Director, Preclinical Development
Tetraneuron - Ángel Lucio Pereira - CEO
Serenatis Bio - David Cavalla - Executive Chairman
Ultimate Medicine - Antal Szalay - CEO
Evox Therapeutics - Per Lundin - CEO & Co-Founder

14:45

**Industry Panel - Partnering With Industry**

**Moderator:** Christian J Suojanen, CEO - Broadreach Global

Jenny Laird	VP, Business Development Neuroscience - Eli Lilly
Richard Reschen	Director, Business Development & Licensing - MSD
Christian Thomsen	Global External CNS Research - Boehringer Ingelheim
Karen LaRoche	Global Head of Business Strategy & Portfolio Innovation - Merz Therapeutics

15:45

**Bio-Neuroscience Awards**

Company Pitch Awards

16:00

**Closing Remarks**

16:15

**END OF SUMMIT - NETWORKING RECEPTION**





# THANK YOU TO OUR SPONSORS

## Gold Sponsors



THERAPEUTICS

Better outcomes for more patients.

## Founding Sponsors



## Bronze Sponsors



## Partners



An Initiative of:	Co-Organized with:
	